skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Products

Show More

Show More

70 Total results for product and free and sample content found

Datamonitor Healthcare

Understand Market Access Trends in the US, Europe and Emerging Markets

14 Nov 2022

Understand Market Access Trends in the US, Europe and Emerging Markets

This essential whitepaper looks at how increased drug spending and a rising desire for expenditure controls are influencing access dynamics across key markets. It is available to you now, for free.

Topic Drug Development Landscape Approvals Drug Review

Medtech Insight

Diagnostics Development For Coronavirus Begins As Second US Patient Tests Positive

By Sue Darcey 27 Nov 2020

Diagnostics_Development_For_Coronavirus_Begins

Bioresearchers at the Centers for Disease Control and Prevention are hoping that diagnostic platforms previously used to develop tests for outbreaks of other epidemic respiratory diseases, including SARS and MERS, can be built on to develop new diagnostics to detect more cases in the current coronavirus outbreak, US infectious disease authorities say. This comes as more patients are monitored around the US for the disease, and a Chicago woman returning from China tests positive.

Topic Approvals Clinical Trials Coronavirus Policy & Regulation

Datamonitor Healthcare

Webinar: Outlook for NASH Therapies and Market Dynamics

By Joseph Haas 04 Nov 2019

Non-alcoholic steatohepatitis (NASH) is poised to become an even greater epidemic and pharma companies of all sizes are competing to be the first to bring a NASH drug to market. Listen to an in-depth discussion about new and repurposed drug exploration treat NASH, as well as deal making, licensing and partnerships activity for the area.

Topic Cell & Gene Therapy Drug Development Landscape Approvals

Datamonitor Healthcare

Insight into NASH Pricing Strategies

By Hannah Cohen 25 Oct 2019

Insight into NASH Pricing Strategies

Explore the key hurdles to anticipating the initial and potential value of the NASH therapy market.

Topic Approvals Business Strategies

Scrip

J&J's Spravato Set For EU Launches Soon

By Kevin Grogan 23 Oct 2019

J_and_Js_Spravato_Set_For_EU_Launches_Soon

Ketamine-Like Antidepressant Backed By CHMP If the nasal spray is approved by the European Commission, seven months after getting the green light in the US, Spravato will offer the first new mechanism of action in 30 years to treat major depressive disorder.

Topic Approvals Drug Development Landscape

Datamonitor Healthcare

Providing Coverage of the Commercial Topics in Q3

10 Oct 2019

Providing Coverage of the Commercial Topics in Q3

The Commercial Solutions Strategy Suite from Informa Pharma Intelligence unites the power of vital tools to bring you actionable data, penetrating analysis, and a crucial industry view covering a variety of critical market aspects, allowing you to accurately Forecast, Analyze and Benchmark, and Understand the mark landscape.   

Topic Approvals Drug Development Landscape

Biomedtracker, Datamonitor Healthcare

Key potential drug launches 2020

27 Sep 2019

Key potential drug launches 2020

Take a longer-term look at key late-stage drugs projected to hit the market in 2020, including new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare.

Topic Approvals Drug Review Drug Development Landscape

Pink Sheet

The Stakes Are High So Get It Right: CHMP Oral Explanations & FDA AdComs

By Neena ​ Brizmohun 09 Aug 2019

The Stakes Are High So Get It Right: CHMP Oral Explanations & FDA AdComs

The stakes are extremely high for companies called before EU or US regulators and scientific experts to answer queries about their new drug applications at the later stages of the review process. How they perform is critical. Consultant Kate Dion has a raft of helpful tips for companies facing this daunting situation. Neena Brizmohun reports.

Topic Approvals

Scrip

UK Committee Attacks Pharma Over Lack Of Medicinal Cannabis Research

By Ian Schofield 12 Jul 2019

UK Committee Attacks Pharma Over Lack Of Medicinal Cannabis Research

The pharmaceutical industry has come under attack by a UK parliament committee for failing to make medicinal cannabis products available for clinical trials, saying that a "robust research base" is needed on which to base future treatment decisions.

Topic Clinical Trials Approvals

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: